Telomerase replicates chromosome ends to facilitate continued cell division. Mutations that compromise telomerase function result in stem cell failure diseases, such as dyskeratosis congenita (DC). One such mutation (K170Δ), residing in the telomerase-recruitment factor TPP1, provides an excellent opportunity to structurally, biochemically, and genetically dissect the mechanism of such diseases. We show through site-directed mutagenesis and X-ray crystallography that this TPP1 disease mutation deforms the conformation of two critical amino acids of the TEL [TPP1's glutamate (E) and leucine-rich (L)] patch, the surface of TPP1 that binds telomerase. Using CRISPRCas9 technology, we demonstrate that introduction of this mutation in a heterozygous manner is sufficient to shorten telomeres in human cells. Our findings rule out dominant-negative effects of the mutation. Instead, these findings implicate reduced TEL patch dosage in causing telomere shortening. Our studies provide mechanistic insight into telomerase-deficiency diseases and encourage the development of gene therapies to counter such diseases.
telomere | telomerase | TPP1 | TEL patch | dyskeratosis congenita T elomerase is a unique ribonuclear protein complex [telomerase reverse transcriptase (TERT): protein subunit; TR: RNA subunit] that synthesizes telomeric DNA repeats (GGTTAG in humans) at chromosome ends to facilitate continued cell division (1) (2) (3) . Although telomerase is not expressed in most normal somatic cells, its presence in stem cells is crucial for their self-renewal (4) . Germ-line mutations in the genes coding for telomerase subunits, or in protein factors important for either telomerase biogenesis or trafficking in the cell, result in genetically inherited diseases, the most prominent of which is dyskeratosis congenita (DC) (5, 6) . DC is clinically diagnosed by the presentation of a classic triad: nail dysplasia, skin hyperpigmentation, and oral leukoplakia. Bone marrow failure resulting from the depletion of the hematopoietic stem cell pool is the primary cause of morbidity and mortality in DC patients. At a molecular level, DC is diagnosed by blood leukocyte telomere lengths of less than the first percentile for age. Despite the devastating nature of this disease, its genetic basis has hampered the development of effective therapies.
The TPP1 (TINT1/PTOP/PIP1) protein (7-9) is a component of the six-membered shelterin complex [TPP1, protection of telomeres protein (POT1), telomeric repeat-binding factor 1 (TRF1), TRF2, Rap1, and TERF1-interacting nuclear factor 2 (TIN2)] that protects chromosome ends from the cellular DNA damage response and repair machineries (10, 11) . TPP1 is a unique shelterin component in that it binds telomerase (12) , recruits telomerase to telomeres (13) , increases telomerase processivity (14) , and facilitates telomere elongation in telomerase-positive cells (15, 16) . Mutagenesis screens revealed a region called the TEL [TPP1's glutamate (E) and leucine-rich (L)] patch, which resides in the structurally characterized oligosaccharideoligonucleotide-binding (OB) domain of the TPP1 protein. The TEL patch is critical for all of the telomerase-associated roles of TPP1 (15) (16) (17) (18) (19) (20) (21) (22) . Central to TEL patch function are three glutamates-E168, E169, and E171 (Fig. 1A) -which, when mutated to alanine (15, 18) or arginine (17) , result in severely compromised telomerase function.
The discovery of the TEL patch of TPP1 prompted the prediction that this region could be a hotspot for mutations that cause telomerase-deficiency diseases, such as DC. We recently reported a case of a severe variant of DC, Hoyeraal-Hreidarsson syndrome (23) , in which the proband was heterozygous for a deletion of a single amino acid of the TPP1 protein, namely lysine 170 (K170) (24) . Our study placed the ACD gene coding for TPP1 protein on a list with 10 other genes (DKC1, TERC, TERT, RTEL1, TINF2, CTC1, NOP10, NHP2, WRAP53, and PARN) that are found mutated in DC and other telomere-related disorders (25) . Indeed, a heterozygous TPP1 K170Δ mutation was also reported in another unrelated family, where it was implicated in causing aplastic anemia and other related hematopoietic complications in the proband (26) . In both families, the presence of the K170Δ mutation correlated strongly with short telomeres. Transient overexpression of K170Δ in cultured human cells resulted in a decrease in telomerase recruitment (24, 26) , and a reduction in the ability of TPP1 to stimulate telomerase processivity (the ability of telomerase to continue DNA synthesis without dissociating from a bound primer) (24) . These results invoke a direct role for the K170Δ mutation in reducing telomerase function in dividing cells. However, it is unknown whether the heterozygous K170Δ mutation is sufficient to cause telomere shortening in dividing human cells without additional genetic modifiers.
The placement of K170 directly adjacent to E168, E169, and E171 strongly suggests that this amino acid facilitates the ability of the TEL patch to recognize telomerase. However, inspection of the crystal structure of the OB domain of WT
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Telomerase is an enzyme that replicates chromosome ends to facilitate continued stem cell division. Mutations in telomerase or in telomerase-related genes result in stem cell-dysfunction diseases, such as dyskeratosis congenita (DC). Despite its devastating nature, DC currently has no cure. Here we report the crystal structure of a mutant protein implicated in DC to reveal how the mutation disrupts a region of the protein essential for telomerase function. Furthermore, we demonstrated that this mutation, when introduced into a human cell line, is sufficient to cause the cellular underpinnings of DC. Our results therefore make the strong prediction that correcting the mutation in the stem cells of the patient will reverse the cellular symptoms of disease.
TPP1 revealed that the side-chains of E168, E169, and E171, but not K170, are exposed to the solvent (Fig. 1A) (14) . This finding suggests that E168, E169, and E171 are poised to interact with telomerase, consistent with the deleterious consequences associated with alanine mutations of these residues (15, 18, 19) . In sharp contrast, the side-chain of K170 is buried in the TPP1-OB structure, making a cation-π interaction with the aromatic ring of W167 (Fig. 1A) . It is therefore unclear how deletion of this residue ultimately translates into reduced telomerase function. Here, we performed a series of biochemical, cytological, genetic, and X-ray crystallographic experiments to show that deletion of K170: (i) disrupts the spatial positioning of critical glutamate residues in the TEL patch; (ii) is sufficient to cause telomere shortening when present in a heterozygous context; and (iii) does not elicit dominant negative effects on the WT protein. Together, these studies provide valuable insights into the role of TPP1 in telomere length regulation, and help reveal the molecular underpinnings of diseases, such as DC.
Results
Deletion of K170, but Not Its Substitution to Alanine, Greatly Reduces Telomerase Processivity. The deleterious effect of the TPP1 K170Δ mutation on telomerase processivity is not because of a defect in binding to POT1 as K170Δ binds POT1 similar to WT TPP1 protein (Fig. S1A) . To further understand the molecular basis of telomerase deficiency caused by this DC mutation, we engineered a K170A mutation in the TPP1-N vector (14) for expression in Escherichia coli. TPP1-N constructs (TPP1 amino acids 90-334) of K170A, WT, K170Δ, and E169A/E171A (EE-AA) proteins were purified as described previously (14, 15) (Fig. S1B) . We performed direct primer extension assays to determine how each of the TPP1-N variants contributes to telomerase processivity in the presence of POT1 (Fig. 1 B and C) . The WT protein displayed the expected increase in telomerase processivity (14) , giving rise to a large fraction of longer DNA products. Both K170Δ and E169A/ E171A failed to increase telomerase processivity to WT TPP1-N levels, as expected from previous studies (Fig. 1 B, and C) (15, 24) . Strikingly, mutation of K170 to alanine resulted in only a modest reduction in telomerase processivity ( Fig. 1 B and C) that was not statistically significant in experiments performed in triplicate (P = 0.08). This result suggests that the positive charge of K170 is not critical for telomerase processivity. In addition, E169D/E171D (E→D mutation that retain negative charge), but not E169Q/ E171Q (E→Q mutations that are iso-steric and polar but lack the negative charge), was able to stimulate telomerase processivity (Fig. S1C ). These results are fully consistent with the structure of TPP1-OB WT, which indicates that the glutamates, but not K170, of the TEL patch loop are accessible to telomerase.
Deletion of K170, but Not Its Substitution to Alanine, Greatly Reduces Telomerase Recruitment to Telomeres and Telomere Lengthening.
Given that deletion of K170 reduces telomerase processivity but substitution of K170 to alanine does not, we next asked how K170A impacts telomerase recruitment. To this end, we engineered HeLa cell lines stably expressing either FLAG-TPP1 K170A or FLAG-TPP1 K170Δ protein using the Flp-recombinase-based single-site integration strategy (15) . We analyzed two clones each of FLAG-TPP1 K170A and FLAG-TPP1 K170Δ in parallel with FLAG-TPP1 WT and E169A/E171A clones that have been characterized previously (15) (see Fig. S2A for FLAG immunoblots). We performed immunofluorescence (IF) to detect FLAG TPP1 and FISH against TR to detect telomerase localization in HeLa cells transiently overexpressing telomerase (15) . The K170A mutation did not negatively impact telomerase recruitment, as telomerase was readily detectable at ∼90% of the FLAG-TPP1 foci in cells stably expressing K170A (Fig. 1 D and E and Fig. S2B ). In sharp contrast, telomerase recruitment was inefficient in K170Δ and E169A/ E171A cells, which exhibited 34% and 7% telomerase recruitment to telomeres, respectively. These studies are in agreement with a previous study showing a severe (∼10-fold) reduction in recruitment of TERT to TPP1-OB E168R that was tethered to a LacO repeat array, but only a modest (<twofold) defect when K170A was used (17) .
Because the K170A mutation had only a modest effect on telomerase recruitment and processivity, we anticipated that overexpression of K170A will elongate telomeres akin to observations with overexpression of WT TPP1 (12, 15, 19) . In contrast, K170Δ overexpression would be expected to result in short telomeres, as observed with E169A/E171A overexpression (15) . Indeed, overexpression of K170A resulted in elongation of telomeres ( Fig. 1F and Fig. S2 C-E). The modest reduction in the slope of telomere lengthening in the two K170A clones compared with the WT clone ( Fig. S2 D and E) is in agreement with similar effects seen in the telomerase processivity and recruitment results presented here and in previous LacO-tethering studies (17) . In sharp contrast, overexpression of K170Δ failed to lengthen telomeres as a function of time in culture ( Fig. 1F and Fig. S2 C-E). The telomere shortening rate and the final telomere length of both K170Δ clones were very similar to that of the E169A/E171A clone shown here and that of other E169A/E171A clones described previously (15) . This is thus a demonstration of a cause-effect relationship between the K170Δ mutation and telomere shortening in human cells, providing the most direct evidence so far for the causative role that this mutation plays in telomere biology disorders.
Deletion of K170 Results in a Major Restructuring of the TEL Patch.
The results presented thus far, considered with the structure of TPP1-OB WT, support the hypothesis that the side-chain of K170 is not involved in binding telomerase directly. To gain a deeper understanding of how this portion of the TEL patch recognizes telomerase, we crystallized TPP1-OB K170Δ and TPP1-OB K170A under conditions similar to those that yielded TPP1-OB WT crystals (14) . We solved the structure of these mutant proteins to 3.0 Å with molecular replacement using the WT structure as the search model (SI Materials and Methods and Table S1 ). The overall 3D structures of the two mutants are very similar to that of the WT structure ( Fig. 2A) . The rmsd of the Cα backbone (total of 282 Cα atoms aligned) for the WT vs. K170Δ, WT vs. K170A, and K170Δ vs. K170A structures were 0.3 Å, 0.4 Å, and 0.3 Å, respectively. However, and consistent with the functional data presented here, a unique feature present in the WT and K170A structures was conspicuously absent in the K170Δ structure. This feature is a bulge in the loop containing residues W167, E168, E169, K170, and E171, that we term the TEL patch "knuckle" (Fig. 1A) . This feature is absent in the K170Δ structure, as can be discerned in the overlay of the overall 3D structures ( Fig. 2A) as well as the 2Fo -Fc electron density for this region (Fig. 2B) . Deletion of the entire K170 residue displaces two of the critical TEL patch glutamates, E168 and E169, by 3.1 Å and 3.6 Å (at Cα positions), respectively, relative to their positions in the WT structure. In contrast, E168 and E169 residues are almost superimposable between the WT and K170A structures (Fig. 2B) . Although the electron density for side-chain atoms in the TEL patch loop is less well-defined compared with that for the main-chain atoms in each of the three structures, it is reasonable to conclude that the large displacements of the Cα positions of E168 and E169 between the WT and K170Δ structures will translate to comparable displacements of the respective side-chain atoms (Fig. S3) . Taken together, our results demonstrate that the main chain atoms of K170 facilitate a conformation of the TEL patch that presents the critical, negatively charged E168 and E169 sidechains for a productive electrostatic interaction with telomerase.
A Single K170Δ Allele Is Sufficient to Cause Telomere Shrinkage in Cultured Human Cells. The data presented thus far provide strong evidence and a structural rationale for a causal role of the TPP1 K170Δ mutation in telomerase dysfunction. However, it is still unclear how this mutation, present in a heterozygous state in two unrelated families (24, 26) , is sufficient to cause severe telomere shortening. It is possible that other disease modifiers cooperate with K170Δ to cause telomere shortening in these families. However, our overexpression studies demonstrating that the K170Δ mutation reduces telomerase function (Fig. 1) support the alternative possibility that reducing the dose of a functional TEL patch to ∼half is sufficient to cause telomere shortening via either haploinsufficiency or dominant-negative effects of the mutation. Such overexpression studies are not suitable for distinguishing between haploinsufficiency versus dominant-negative effects, because TPP1 overexpression in these cells is ∼25-fold above endogenous levels (15) . The overexpressed mutant protein will completely replace endogenous WT protein at telomeres [because of competition of binding to TIN2, which recruits TPP1 to telomeres (27) ], causing the telomeres to resemble the homozygous state. To recapitulate the heterozygous nature of K170Δ in the absence of overexpression caveats, we introduced the K170Δ mutation in HEK 293T cells using CRISPR-Cas9 technology (28, 29) . Fig. 3A shows the general scheme for cleavage of the ACD gene (which codes for the TPP1 protein) by three guide RNAs (g1, g2, and g3). Using transient transfection of plasmids encoding Cas9 and guide RNAs, we observed efficient cleavage of the gene coding for TPP1 with each of the three guide RNAs, and with a mixture of the three guides (as inferred from the Surveyor nuclease assay) ( Fig. 3B and SI Materials and Methods). We were unable to detect the cleavage of the top predicted off-targets (30) of guide RNAs 2 or 3 (Fig. S4A) . Based on these results, we proceeded to cleave the ACD locus in HEK 293T cells using a combination of guides 2 and 3. Mutagenic single-stranded oligodeoxyribonucleotide donors (ssODNs) were used as the substrate for homology-directed repair of the cleaved locus.
To introduce precise changes in the human ACD gene coding for human TPP1 protein, we designed two different ssODNs: the first contained the K170Δ mutation, whereas the second harbored only silent mutations in the coding region of TPP1 (Fig.  3A) . The latter ssODN, upon integration in the genome, would yield cells expressing WT TPP1. However, these cells would have been subjected to the same conditions (e.g., identical guide RNA-mediated cleavage) experienced by K170Δ-edited cells. These silently edited WT cells, which we refer to as WT* cells, served as the control against which we compared K170Δ-edited cells. Each ssODN contained additional silent mutations to serve two purposes. The first set of silent mutations destroyed the protospacer adjacent motif (PAM) sequences to prevent cleavage of the gene coding for TPP1 by Cas9 postrepair (Fig. 3A) . The second set of silent mutations introduced a KpnI restriction site to facilitate the screening of clones (Fig. 3A) . Evidence for editing was readily observed in both WT* and K170Δ transfection experiments based on the results of the KpnI screening assay (SI Materials and Methods and Fig. S4B ). The fraction of the intensities of the digestion products relative to that of the undigested products indicated the efficiency of intended mutagenesis (i.e., fraction of HEK 293T cells that were edited), which we determined to be ∼5%. Next, we proceeded to isolate clones containing the K170Δ (or the WT*) mutation by diluting these transfected cells.
We isolated clones that contained either the WT* mutation or the K170Δ mutation. The presence of the edited alleles was inferred from KpnI digestion profiles and Sanger DNA sequencing of the ACD locus (Fig. 3C, Fig. S4C , and Table S2 ). Sanger DNA sequencing of the ACD locus in all isolated clones was consistent with the presence of three alleles coding for TPP1 A B Fig. 2 . Deletion of K170 restructures the loop that harbors the critical glutamate residues of the TEL patch of TPP1. (A) Ribbon diagrams of TPP1-OB K170Δ (red, Left) and TPP1-OB K170A (tan, Center) along with the overlay of these structures on the structure of TPP1-OB WT (WT in green, Right).
(B) Overlay of the backbone traces for amino acids 166-171 of the three structures along with the 2Fo -Fc electron density for TPP1-OB K170Δ contoured at 1.1 σ (Left); or the 2Fo -Fc electron density for TPP1-OB K170A contoured at 1.1 σ (Center); or without any electron density displayed (Right). Single arrowheads indicate the TEL patch knuckle, and the double-headed arrows indicate the displacement of E168 and E169 in TPP1-OB K170Δ relative to their positions in the WT structure. The PDB code for the previously published TPP1-OB WT structure is 2I46.
protein in HEK 293T cells. This was also in agreement with chromosome-specific centromere FISH experiments showing that HEK 293T cells are triploid for chromosome 16, which contains the gene coding for TPP1 (Fig. S4D) . Partial but not total digestion by KpnI of PCR amplicons spanning the edited site suggested that the WT* and K170Δ clones were heterozygous for the engineered mutations (Fig. 3C and Fig. S4C ). DNA sequencing further revealed that in all WT* and K170Δ clones, the third allele underwent erroneous repair that resulted in gross insertion/deletion mutations ("indels") in the TPP1 open reading frame (ORF) (detailed sequence information in Table S2 ). Therefore, the WT* clone was biallelic for WT TPP1 TEL patch function (Δ/wt*/wt*), representing more closely the status of TPP1 in normal human cells (Fig. 3C and Table S2 ). The two clones containing K170Δ were also biallelic for the gene coding for TPP1, containing one K170Δ allele and one WT allele (Δ/K170Δ/wt), representative of the K170Δ genotype in individuals harboring this mutation (Fig. 3C, Fig. S4C , and Table  S2 ). All of the biallelic clones showed a reduction in TPP1 protein levels compared with the unedited cell line, as expected from the loss of one allele (Fig. S4E) .
We performed TRF blots to determine the effect of the heterozygous K170Δ mutation on telomere length. The WT* clone maintained telomere length in a stable manner similar to unedited HEK 293T cells (Fig. 3D and Fig. S4F ). This result suggests that two copies of the gene coding for TPP1 are sufficient for telomere length maintenance in HEK 293T cells; and that our genome editing strategy did not result in any unexpected changes in telomere length. Both clones that were heterozygous for the K170Δ mutation showed telomere shortening as a function of time in culture (Fig. 3D and Fig. S4F ). This result demonstrates that a single copy of the K170Δ allele is sufficient to decrease telomere length in proliferating human cells.
Presence of K170Δ Does Not Alter the Ability of WT TPP1 to Facilitate
Telomerase Function. The ability of a single TPP1 K170Δ allele to elicit telomere shortening may be explained either by dominantnegative effects of the mutant protein on the WT protein or simply by a reduced dosage of WT TPP1 protein. The possibility of a dominant-negative mechanism becomes relevant in light of a study invoking TPP1 dimerization through its OB domain in an Akt1-mediated phosphorylation-dependent manner (31) . Some studies also suggest that the human telomerase holoenzyme functions as a homodimer, although other studies contradict this notion (32, 33) . To directly test for dominant-negative effects of the TPP1 K170Δ protein, we first performed telomerase-catalyzed primer-extension assays involving two types of mutant-WT TPP1 protein-mixing experiments. In the first type of experiment, all reactions included TPP1-N WT protein at a constant concentration of 200 nM (and POT1 protein at a constant concentration of 500 nM). TPP1-N K170Δ was titrated into these reaction mixtures (before addition of telomerase). As shown in Fig. 4A , addition of TPP1-N WT in the absence of K170Δ shows the characteristic stimulation of telomerase processivity (Fig. 4A, compare lanes 1  and 2) (14, 15) . Addition of TPP1-N K170Δ protein in sub-or superstoichiometric amounts to 200 nM TPP1-N WT failed to reduce telomerase processivity (Fig. 4A, compare lanes 3-5 with  lane 2) . In the second experiment, we added increasing amounts of WT TPP1 protein to reactions containing K170Δ protein held at a constant concentration of 200 nM. Substoichiometric amounts of WT protein were sufficient to stimulate telomerase processivity in the presence of 200 nM K170Δ protein (Fig. 4A, compare lanes  14-16 with lane 10) . These results suggest that the K170Δ protein does not exert any negative effects over the ability of WT TPP1 protein to stimulate telomerase processivity in vitro. Next, we performed mutant-WT TPP1 mixing telomerase recruitment experiments in HeLa cells using IF-FISH. In these experiments, we transfected HeLa cells with a myc-tagged TPP1 WT-expressing plasmid (plus an empty vector plasmid), a FLAGtagged TPP1 K170Δ-expressing plasmid (plus an empty vector plasmid), or a mixture of plasmids for myc-tagged TPP1 WT and FLAG-tagged TPP1 K170Δ coexpression. Coexpression of TPP1 WT protein at levels comparable to that of TPP1 K170Δ (Fig.  S5A ) resulted in the efficient rescue of the telomerase recruitment defect (Fig. 4B) . We conclude from these experiments that TPP1 WT colocalizing with TPP1 K170Δ at telomeres is able to recruit telomerase to these foci.
Next, we performed telomere ChIP experiments (13) . For this, HeLa 1.2.11 cells were transfected with plasmids encoding TERT, TR, and either TPP1 WT, TPP1 K170Δ, or a mixture of plasmids to express both TPP1 constructs. Immunoprecipitations were performed with an anti-TERT antibody and the associated telomeric DNA signal was detected using Southern dot blots (Fig.  S5B) . Although an ∼20% reduction in the amount of telomerase associated with telomeres was observed for K170Δ relative to WT, there was no evidence of a telomerase recruitment defect when a mixture of the TPP1 constructs was present in the cells.
Finally, we performed a CRISPR-Cas9 knockout experiment to isolate HEK 293T clones containing only one functional copy of the gene coding for TPP1 (Δ/Δ/wt). Comparison of these cells to the K170Δ-edited cells described above (Δ/K170Δ/wt) could reveal any dominant-negative effects of K170Δ. Using the same CRISPR-Cas9 strategy described above, we isolated a HEK 293T clone that contained only one unedited allele of the gene coding for TPP1 (Δ/Δ/wt) ( Table S2 ). As expected, the TPP1 protein level in Δ/Δ/wt cells was less than in Δ/wt/wt cells or in unedited cells (wt/wt/wt) (Fig. S6A) . Telomere length measurements as a function of time in culture demonstrated that Δ/Δ/wt cells exhibited robust telomere shrinkage (Fig. 4C) . Telomere shortening in Δ/Δ/wt cells was accelerated compared with that in Δ/K170Δ/wt cells (Fig. S6B) , clearly ruling out any dominantnegative effect of the K170Δ mutation. The milder telomere shortening phenotype in Δ/K170Δ/wt cells compared with the Δ/Δ/wt cells is consistent with the modest (yet reproducible) ability of TPP1 K170Δ protein to stimulate telomerase processivity relative to the "no TPP1" control ( Fig. 1 B and C) .
Combined, our biochemical and cytological experiments failed to reveal a dominant-negative role of the K170Δ mutation in telomerase action. Therefore, telomere shrinkage in cells of individuals harboring the TPP1 K170Δ mutation is likely caused by reduced dosage of a functional TEL patch.
Discussion
Here, we solved the structure of a human protein mutant associated with DC. The TPP1-OB K170Δ structure clearly reveals the loss of a structural motif that we term the TEL patch "knuckle." Loss of this motif rearranges the spatial positioning of glutamates E168 and E169 that are critical for telomerase recruitment and action at telomeres. Our structures provide a straightforward structural rationale for telomerase-deficiency caused by K170Δ, and inspire the search for small molecules that can rescue the telomerase-binding defect of the K170Δ mutation. In addition, our structures also detail the precise contribution of the affected amino acid K170 to telomerase function. Given that K170A does not substantially alter stimulation of telomerase processivity, telomerase recruitment, or the conformation of the TEL patch knuckle, we conclude that K170 sidechain does not bind telomerase directly, but rather facilitates a productive TEL patch conformation for binding telomerase. The modest reduction in telomerase function caused by K170A observed here and in previous studies (17) is not easily explained by our crystal structures. We envision that the cation-π interaction between the K170 side-chain and W167 (Fig. 1A) contributes to the dynamics (or lack thereof) of the TEL patch knuckle in a manner that is (modestly) conducive to telomerase binding, but not captured by our (static) crystal structures. Gene therapy against DC will only be effective or justified if the disease mutation is sufficient to cause the underlying cellular phenotype (telomere shortening). Here, we used CRISPR-Cas9 technology to introduce the K170Δ mutation in HEK 293T cells. Our results clearly demonstrate that presence of a single allele of K170Δ is sufficient to reduce telomere length, ruling out the necessity of other genetic modifiers to elicit this effect. This is especially pertinent to the individual with Hoyeraal-Hreidarsson syndrome in our recent study, who inherited a TPP1 P491T variant (on a separate allele) in addition to the K170Δ mutation (24) . Our studies make the prediction that reversing the K170Δ mutation in the presence (or absence) of P491T will stall telomere shortening. However, our gene-editing studies are limited to one cell line. In this regard, a previous study by Sexton et al. (16) in human embryonic stem cells (hESCs) failed to elicit a telomere length phenotype when a TPP1 mutant lacking residues 166-172 was expressed in a heterozygous context. Regardless of the precise factors influencing the telomere length phenotype in these studies (see SI Text for a description of possibilities), these contextdependent phenotypes highlight the challenges that lie ahead for gene therapies targeted at genetically defined diseases like DC.
The heterozygous nature of the TPP1 disease mutation raises the possibility of potential dominant-negative effects, arising from the ability of TPP1 and telomerase to dimerize, driving telomerase deficiency in the proband. We performed protein-mixing experiments to directly test the effect of K170Δ on TPP1 WT function. Neither the telomerase processivity nor the telomerase recruitment WT-mutant mixing experiments (IF-FISH and telomere ChIP) revealed any evidence for a dominant-negative effect for K170Δ. Assuming that our mixing experiments recapitulated the functionally relevant oligomeric status (if any) of TPP1 and telomerase in the cells, we conclude that the TEL patch performs its function independent of the oligomeric status of TPP1 or telomerase. Finally, the TPP1 Δ/Δ/wt cells that we engineered showed robust telomere shortening, further ruling out the involvement of any dominant-negative effects of the TPP1 K170Δ mutation in human cells.
In conclusion, the K170Δ mutation in TPP1 provided us a unique opportunity to dissect the structural, biochemical, and genetic underpinnings of a case of DC, yielding valuable insights into disease mechanism and encouraging therapeutic strategies to counter this disease.
Materials and Methods
Protein expression and purification, telomerase activity assays, immunoblotting, IF and FISH microscopy, stable cell line generation using HeLa-EM2-11ht cells, and telomere length analysis were performed using published protocols (15, 24) . TPP1-OB K170Δ and TPP1-OB K170A crystal structures were solved by molecular replacement using the WT structure (PDB ID code 2I46) as a template (14) . CRISPR-Cas9 involving experiments were performed following published protocols (30) . See SI Materials and Methods for full details.
